| pubmed-article:8478664 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0332835 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:8478664 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:8478664 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8478664 | pubmed:dateCreated | 1993-5-24 | lld:pubmed |
| pubmed-article:8478664 | pubmed:abstractText | To evaluate an intensive therapy regimen of high-dose etoposide and melphalan and autologous bone marrow transplantation (ABMT) in advanced Hodgkin's disease; and to determine possible prognostic factors that predict for long-term disease-free survival (DFS). | lld:pubmed |
| pubmed-article:8478664 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8478664 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8478664 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8478664 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8478664 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8478664 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8478664 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8478664 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:SmithA MAM | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:MurrayCC | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:SuttonD MDM | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:ScottJ GJG | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:CoutureFF | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:McCraeJJ | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:PantalonyDD | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:BrandweinJJ | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:CrumpMM | lld:pubmed |
| pubmed-article:8478664 | pubmed:author | pubmed-author:SherretHH | lld:pubmed |
| pubmed-article:8478664 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8478664 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8478664 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8478664 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8478664 | pubmed:pagination | 704-11 | lld:pubmed |
| pubmed-article:8478664 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:meshHeading | pubmed-meshheading:8478664-... | lld:pubmed |
| pubmed-article:8478664 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8478664 | pubmed:articleTitle | High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. | lld:pubmed |
| pubmed-article:8478664 | pubmed:affiliation | University of Toronto Autologous Bone Marrow Transplant Program, Canada. | lld:pubmed |
| pubmed-article:8478664 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8478664 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8478664 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8478664 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8478664 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8478664 | lld:pubmed |
